All In Biotech

Drug Trial Radar · NCT00926562

A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients

A Randomized, Double-blinded Comparison of Iopromide and Iodixanol in Renally Impaired Patients Undergoing Cardiac Catheterization

Last checked: Nov 19, 2026Latest source record: Jun 27, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 592 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

592

Actual

Start

Feb 2009

Primary completion

Dec 2010

Study completion May 2011

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators intend to find out which contrast agent has less kidney toxicity in renal impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).

Conditions

  • Kidney Failure, Chronic

Interventions

  • Iopromide (Ultravist)Drug

    Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM

  • Iodixanol (Visipaque)Drug

    Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients exhibiting a relative increase in serum creatinine >= 50% from baseline.Time frame: day 3 postreatment

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing CHAO-YANG Hospital

    Beijing, Beijing Municipality, China

  • General Hospital of Armed Police Forces

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Beijing Shi Jing Shan Hospital

    Beijing, Beijing Municipality, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Chinese PLA general hospital

    Beijing, Beijing Municipality, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Wuhan Asia Heart Hospital

    Wuhan, Hubei, China

  • The Second Hospital of Xiangya

    Changsha, Hunan, China

  • China-Japan Union Hospital of Jilin University

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jinlin, China

  • Shanghai First People's Hospital

    Shanghai, Shanghai Municipality, China

  • Renji Hospital affiliated to Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, China

  • Changhai Hospital affiliated to the second millitary medical university

    Shanghai, Shanghai Municipality, China

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality, China

  • Teda International Cardiovascular Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Hospital Affiliated to Zhejiang University

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital affiliated to Zhejiang

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.